Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here

UBS raised the firm's price target on Biohaven to $60 from $59 and keeps a Buy rating on the shares after hosting meetings with management. The stock's 28% selloff since April 15 represents an "attractive opportunity," the analyst tells investors in a research note. The firm sees an attractive risk/reward into the Phase 1 degrader data on May 29. A key opinion leader viewed Biohaven's degrader platform as an elegant approach to various disease modalities, says UBS. The firm says the stock's bear case is overdone.